Inclusion Criteria:  Adults older than 18 and younger than 50 years, with a weight higher than 40 kg Positive conventional confirmatory serology for T. cruzi infection from the NAtional Public Health institute (ISPCH), and A positive qPCR Have normal laboratory test values for the following parameters: total white blood cell count, platelet count, creatine kinase (CK), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin or creatinine, or a gamma-glutamyl transferase (GGT) > 2 times the upper limit of normal (X ULN); Women of reproductive age must have a negative serum pregnancy test, must not be breastfeeding, and must consistently use a highly effective contraceptive method throughout the treatment phase Ability to comply with all protocol-specified follow-up tests and visits and have a permanent address; Signed written informed consent form  Exclusion Criteria:  Signs and symptoms of the digestive form of Chagas Disease; Chronic cardiac Chagas Disease stage II or higher; Acute or chronic health conditions such as acute infections, history of HIV infection, diabetes, liver and kidney disease; Hypothyroidism Family history of muscle disorders Pre-existing heart disease unrelated to Chagas disease; Formal contraindication to receive nifurtimox or benznidazole, Known history of hypersensitivity, allergy or severe adverse reactions to atorvastatin, benznidazole or nifurtimox; History of previous treatment for Chagas Disease; History of prior treatment with atorvastatin, lovastatin, rosuvastatin, simvastatin or any other statin; Any concomitant use of antimicrobial agents; History of alcohol or drug abuse; Any condition that precludes oral medication; Concomitant or intended use of CYP3A4 modifiers; Medical history of familial short QT syndrome or concomitant therapy with medications that may shorten the QT interval. Abnormal laboratory test values for the following parameters: total white blood cell count, platelet count, creatine kinase (CK), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin or creatinine, or a gamma-glutamyl transferase (GGT) > 2 times the upper limit of normal (X ULN); Being pregnant or breastfeeding Refusing to use a highly effective contraceptive method during the treatment phase.